Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 12

1.

Low density granulocytes are increased in the antiphospholipid syndrome and are associated with anti-β2GPI antibodies: Comment on the article by Yalavarthi et al.

van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR.

Arthritis Rheumatol. 2016 Jan 8. doi: 10.1002/art.39576. [Epub ahead of print] No abstract available.

PMID:
26749538
2.

Delineating the deranged immune system in the antiphospholipid syndrome.

van den Hoogen LL, van Roon JA, Radstake TR, Fritsch-Stork RD, Derksen RH.

Autoimmun Rev. 2016 Jan;15(1):50-60. doi: 10.1016/j.autrev.2015.08.011. Epub 2015 Aug 28. Review.

PMID:
26318678
3.

Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond.

van den Hoogen LL, Sims GP, van Roon JA, Fritsch-Stork RD.

Curr Aging Sci. 2015;8(2):158-77.

PMID:
26212055
4.

Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?

Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J, Ruffatti A, Ambrozic A, Botta A, Le Guern V, Fritsch-Stork R, Nicaise-Roland P, Carbonne B, Carbillon L, Fain O.

Autoimmun Rev. 2015 Jan;14(1):23-9. doi: 10.1016/j.autrev.2014.08.040. Epub 2014 Aug 30. Review.

PMID:
25179813
5.

Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus.

Van Avondt K, Fritsch-Stork R, Derksen RH, Meyaard L.

PLoS One. 2013 Oct 18;8(10):e78459. doi: 10.1371/journal.pone.0078459. eCollection 2013.

6.

The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science.

Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH.

Autoimmun Rev. 2013 Mar;12(5):617-28. doi: 10.1016/j.autrev.2012.12.001. Epub 2012 Dec 8. Review.

PMID:
23232124
7.

Nongenomic glucocorticoid signaling: new targets for immunosuppressive therapy?

Schoneveld JL, Fritsch-Stork RD, Bijlsma JW.

Arthritis Rheum. 2011 Dec;63(12):3665-7. doi: 10.1002/art.30635. No abstract available.

8.
9.

International rheumatology networking: The 2008 American College of Rheumatology/European League Against Rheumatism exchange program.

Hueber AJ, Distler JH, Fritsch-Stork RD.

Arthritis Rheum. 2009 Jul;60(7):1881-3. doi: 10.1002/art.24663. No abstract available.

10.

Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.

Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE.

Arthritis Res Ther. 2009;11(3):R84. doi: 10.1186/ar2718. Epub 2009 Jun 5.

11.

Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE.

Fritsch-Stork RD, Leguit RJ, Derksen RH.

Nat Rev Rheumatol. 2009 May;5(5):283-7. doi: 10.1038/nrrheum.2009.49.

PMID:
19412195
12.

The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus.

Fritsch-Stork R, Müllegger D, Skriner K, Jahn-Schmid B, Smolen JS, Steiner G.

Arthritis Res Ther. 2006;8(4):R118.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk